{"transactions":[{"id":746456,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:21:07.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":3.06,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-041579","document":"wk-form4_1780950062.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026041579/wk-form4_1780950062.xml","form_type":"4"}},{"id":748017,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:45:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":19226,"derivative":{"exercise_price":19.66,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19226},"source":{"system":"sec-edgar","filing":"0001578200-26-000004","document":"wk-form4_1780692324.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000157820026000004/wk-form4_1780692324.xml","form_type":"4"}},{"id":748016,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:45:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,408 unvested RSUs."}],"balance_after":21665,"source":{"system":"sec-edgar","filing":"0001578200-26-000004","document":"wk-form4_1780692324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000157820026000004/wk-form4_1780692324.xml","form_type":"4"}},{"id":948755,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-01-06T21:14:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1962,"derivative":{"exercise_price":772.76,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":1962},"source":{"system":"sec-edgar","filing":"0001578200-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000157820026000002/edgardoc.xml","form_type":"4"}},{"id":948754,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:14:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":603,"source":{"system":"sec-edgar","filing":"0001578200-26-000002","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000157820026000002/edgardoc.xml","form_type":"4"}},{"id":1074906,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:37.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":4.04,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-25-000050","document":"wk-form4_1754441010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000050/wk-form4_1754441010.xml","form_type":"4"}},{"id":1074905,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:37.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.68,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-25-000050","document":"wk-form4_1754441010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000050/wk-form4_1754441010.xml","form_type":"4"}},{"id":1074904,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:37.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":39062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":39062,"derivative":{"exercise_price":4.04,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-25-000050","document":"wk-form4_1754441010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000050/wk-form4_1754441010.xml","form_type":"4"}},{"id":1074903,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-06T00:43:37.000Z","date":"2025-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of August 1, 2025 (the \"Repricing Date\"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the \"2019 Plan\") and/or the 2022 Stock Option and Incentive Plan (the \"2022 Plan\" and, together with the 2019 Plan, the \"Plans\"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.83,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-25-000050","document":"wk-form4_1754441010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456225000050/wk-form4_1754441010.xml","form_type":"4"}},{"id":1121573,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T22:14:03.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":1.32,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001628280-25-029774","document":"wk-form4_1749161387.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025029774/wk-form4_1749161387.xml","form_type":"4"}},{"id":1121374,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:26:51.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000138","document":"wk-form4_1749155084.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000138/wk-form4_1749155084.xml","form_type":"4"}},{"id":1121373,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:26:51.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":15257,"source":{"system":"sec-edgar","filing":"0001714899-25-000138","document":"wk-form4_1749155084.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000138/wk-form4_1749155084.xml","form_type":"4"}},{"id":1312123,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-01-06T22:42:19.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":1958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1958,"derivative":{"exercise_price":719.37,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":1958},"source":{"system":"sec-edgar","filing":"0001968202-25-000012","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000012/edgardoc.xml","form_type":"4"}},{"id":1312122,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-06T22:42:19.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":448,"source":{"system":"sec-edgar","filing":"0001968202-25-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820225000012/edgardoc.xml","form_type":"4"}},{"id":1366626,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":false,"shares":47165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2027-12-06","underlying":"Common Stock","underlying_shares":47165},"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1366625,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":32312,"price":32.87,"value":1062095.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.54 to $33.28 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,967 Unvested RSUs."}],"balance_after":9220,"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1366624,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":27129,"price":32.09,"value":870569.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.54 to $32.53 per share. Upon request by the Commission staff, the Issuer, or a\nsecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,967 Unvested RSUs."}],"balance_after":41532,"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1366623,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T21:18:59.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":true,"shares":47165,"price":18,"value":848970.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,967 Unvested RSUs."}],"balance_after":68661,"source":{"system":"sec-edgar","filing":"0001714899-24-000219","document":"wk-form4_1731532732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000219/wk-form4_1731532732.xml","form_type":"4"}},{"id":1470589,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2024-06-24T20:09:40.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":11774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025."}],"balance_after":11774,"derivative":{"exercise_price":42.45,"expiration_date":"2034-06-20","underlying":"Common stock","underlying_shares":11774},"source":{"system":"sec-edgar","filing":"0001439222-24-000102","document":"wk-form4_1719259772.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000102/wk-form4_1719259772.xml","form_type":"4"}},{"id":1470588,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-24T20:09:40.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2120,"derivative":{"underlying":"Common stock","underlying_shares":2120},"source":{"system":"sec-edgar","filing":"0001439222-24-000102","document":"wk-form4_1719259772.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000102/wk-form4_1719259772.xml","form_type":"4"}},{"id":1477206,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-17T21:29:37.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":false,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-24-000087","document":"wk-form4_1718659770.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000087/wk-form4_1718659770.xml","form_type":"4"}},{"id":1477205,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-06-17T21:29:37.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":126242,"source":{"system":"sec-edgar","filing":"0001439222-24-000087","document":"wk-form4_1718659770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000087/wk-form4_1718659770.xml","form_type":"4"}},{"id":1479384,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:59:16.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 12, 2025 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date"}],"balance_after":45000,"derivative":{"exercise_price":7.68,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001894562-24-000040","document":"wk-form4_1718398747.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456224000040/wk-form4_1718398747.xml","form_type":"4"}},{"id":1492395,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-04T22:29:25.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":17901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17901,"derivative":{"exercise_price":18.56,"expiration_date":"2034-05-31","underlying":"Common Stock","underlying_shares":17901},"source":{"system":"sec-edgar","filing":"0001714899-24-000136","document":"wk-form4_1717540157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000136/wk-form4_1717540157.xml","form_type":"4"}},{"id":1492394,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:29:25.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":5967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 unvested RSUs."}],"balance_after":21496,"source":{"system":"sec-edgar","filing":"0001714899-24-000136","document":"wk-form4_1717540157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000136/wk-form4_1717540157.xml","form_type":"4"}},{"id":1609884,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-02-29T21:05:13.000Z","date":"2024-02-27","kind":"exercise","planned":false,"acquired":false,"shares":57471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was originally granted on March 5, 2014 for the purchase of 148,770 shares of common stock. The shares underlying this option vested as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":57471},"source":{"system":"sec-edgar","filing":"0001439222-24-000042","document":"wk-form4_1709240674.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000042/wk-form4_1709240674.xml","form_type":"4"}},{"id":1609883,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-02-29T21:05:13.000Z","date":"2024-02-27","kind":"exercise","planned":false,"acquired":false,"shares":11858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was originally granted on March 5, 2014 for the purchase of 148,770 shares of common stock. The shares underlying this option vested as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":57471,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":11858},"source":{"system":"sec-edgar","filing":"0001439222-24-000042","document":"wk-form4_1709240674.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000042/wk-form4_1709240674.xml","form_type":"4"}},{"id":1609882,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-29T21:05:13.000Z","date":"2024-02-27","kind":"sale","planned":false,"acquired":false,"shares":57471,"price":34.89,"value":2005163.19,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $34.64 to $35.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":122854,"source":{"system":"sec-edgar","filing":"0001439222-24-000042","document":"wk-form4_1709240674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000042/wk-form4_1709240674.xml","form_type":"4"}},{"id":1609881,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-29T21:05:13.000Z","date":"2024-02-27","kind":"exercise","planned":false,"acquired":true,"shares":57471,"price":31.64,"value":1818382.44,"ownership":{"direct":true},"balance_after":180325,"source":{"system":"sec-edgar","filing":"0001439222-24-000042","document":"wk-form4_1709240674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000042/wk-form4_1709240674.xml","form_type":"4"}},{"id":1609880,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-29T21:05:13.000Z","date":"2024-02-27","kind":"sale","planned":false,"acquired":false,"shares":11858,"price":33.6,"value":398428.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $33.02 to $34.41. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":122854,"source":{"system":"sec-edgar","filing":"0001439222-24-000042","document":"wk-form4_1709240674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000042/wk-form4_1709240674.xml","form_type":"4"}},{"id":1609879,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-29T21:05:13.000Z","date":"2024-02-27","kind":"exercise","planned":false,"acquired":true,"shares":11858,"price":31.64,"value":375187.12,"ownership":{"direct":true},"balance_after":134712,"source":{"system":"sec-edgar","filing":"0001439222-24-000042","document":"wk-form4_1709240674.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000042/wk-form4_1709240674.xml","form_type":"4"}},{"id":1615440,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-02-27T21:04:46.000Z","date":"2024-02-26","kind":"exercise","planned":false,"acquired":false,"shares":20411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was originally granted on March 5, 2014 for the purchase of 148,770 shares of common stock. The shares underlying this option vested as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":69329,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":20411},"source":{"system":"sec-edgar","filing":"0001439222-24-000040","document":"wk-form4_1709067874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000040/wk-form4_1709067874.xml","form_type":"4"}},{"id":1615439,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-02-27T21:04:46.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":false,"shares":47731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was originally granted on March 5, 2014 for the purchase of 148,770 shares of common stock. The shares underlying this option vested as to 25% of the underlying shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":89740,"derivative":{"exercise_price":31.64,"expiration_date":"2024-03-04","underlying":"Common stock","underlying_shares":47731},"source":{"system":"sec-edgar","filing":"0001439222-24-000040","document":"wk-form4_1709067874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000040/wk-form4_1709067874.xml","form_type":"4"}},{"id":1615438,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-27T21:04:46.000Z","date":"2024-02-26","kind":"sale","planned":false,"acquired":false,"shares":20411,"price":33.19,"value":677441.09,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $33.00 to $33.59. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":122854,"source":{"system":"sec-edgar","filing":"0001439222-24-000040","document":"wk-form4_1709067874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000040/wk-form4_1709067874.xml","form_type":"4"}},{"id":1615437,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-27T21:04:46.000Z","date":"2024-02-26","kind":"exercise","planned":false,"acquired":true,"shares":20411,"price":31.64,"value":645804.04,"ownership":{"direct":true},"balance_after":143265,"source":{"system":"sec-edgar","filing":"0001439222-24-000040","document":"wk-form4_1709067874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000040/wk-form4_1709067874.xml","form_type":"4"}},{"id":1615436,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-27T21:04:46.000Z","date":"2024-02-23","kind":"sale","planned":false,"acquired":false,"shares":47731,"price":33.05,"value":1577509.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $33.00 to $33.27. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":122854,"source":{"system":"sec-edgar","filing":"0001439222-24-000040","document":"wk-form4_1709067874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000040/wk-form4_1709067874.xml","form_type":"4"}},{"id":1615435,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-02-27T21:04:46.000Z","date":"2024-02-23","kind":"exercise","planned":false,"acquired":true,"shares":47731,"price":31.64,"value":1510208.84,"ownership":{"direct":true},"balance_after":170585,"source":{"system":"sec-edgar","filing":"0001439222-24-000040","document":"wk-form4_1709067874.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000040/wk-form4_1709067874.xml","form_type":"4"}},{"id":1689477,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-01-04T21:17:15.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":508,"derivative":{"exercise_price":888.34,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":508},"source":{"system":"sec-edgar","filing":"0001883850-24-000003","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000003/edgardoc.xml","form_type":"4"}},{"id":1689476,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:17:15.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":42,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":282,"source":{"system":"sec-edgar","filing":"0001883850-24-000003","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385024000003/edgardoc.xml","form_type":"4"}},{"id":1783459,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-09-12T20:04:48.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":2739,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":2739,"derivative":{"exercise_price":833.23,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":2739},"source":{"system":"sec-edgar","filing":"0001104659-23-099992","document":"tm2325700-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099992/tm2325700-4_4seq1.xml","form_type":"4"}},{"id":1783458,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-12T20:04:48.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":240,"source":{"system":"sec-edgar","filing":"0001104659-23-099992","document":"tm2325700-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923099992/tm2325700-4_4seq1.xml","form_type":"4"}},{"id":1845089,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2023-06-23T20:34:47.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4975},"source":{"system":"sec-edgar","filing":"0001439222-23-000091","document":"wk-form4_1687552477.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000091/wk-form4_1687552477.xml","form_type":"4"}},{"id":1845088,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-06-23T20:34:47.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":122854,"source":{"system":"sec-edgar","filing":"0001439222-23-000091","document":"wk-form4_1687552477.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000091/wk-form4_1687552477.xml","form_type":"4"}},{"id":1852722,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T21:50:26.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":39062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 14, 2024 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":39062,"derivative":{"exercise_price":14.83,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":39062},"source":{"system":"sec-edgar","filing":"0001894562-23-000027","document":"wf-form4_168695221480502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456223000027/wf-form4_168695221480502.xml","form_type":"4"}},{"id":1854213,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2023-06-15T20:26:26.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":18958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024."}],"balance_after":18958,"derivative":{"exercise_price":26.56,"expiration_date":"2033-06-13","underlying":"Common stock","underlying_shares":18958},"source":{"system":"sec-edgar","filing":"0001439222-23-000081","document":"wk-form4_1686860775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000081/wk-form4_1686860775.xml","form_type":"4"}},{"id":1854212,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2023-06-15T20:26:26.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":3388,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-23-000081","document":"wk-form4_1686860775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000081/wk-form4_1686860775.xml","form_type":"4"}},{"id":1867183,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T22:04:09.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":12649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":12649,"derivative":{"exercise_price":30.92,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":12649},"source":{"system":"sec-edgar","filing":"0001714899-23-000096","document":"wk-form4_1686002638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000096/wk-form4_1686002638.xml","form_type":"4"}},{"id":1867182,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T22:04:09.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 unvested RSUs."}],"balance_after":15529,"source":{"system":"sec-edgar","filing":"0001714899-23-000096","document":"wk-form4_1686002638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000096/wk-form4_1686002638.xml","form_type":"4"}},{"id":1924887,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-04-05T20:03:37.000Z","date":"2023-04-03","kind":"exercise","planned":true,"acquired":false,"shares":16363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock.  The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone.  The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares.  On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares."}],"balance_after":0,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-29","underlying":"Common stock","underlying_shares":16363},"source":{"system":"sec-edgar","filing":"0001439222-23-000058","document":"wf-form4_168072499813992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000058/wf-form4_168072499813992.xml","form_type":"4"}},{"id":1924886,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-04-05T20:03:37.000Z","date":"2023-04-03","kind":"sale","planned":true,"acquired":false,"shares":16363,"price":22.85,"value":373894.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $22.49 to $23.42. The reporting person undertakes, upon request by the staff of the Securitiesand Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-23-000058","document":"wf-form4_168072499813992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000058/wf-form4_168072499813992.xml","form_type":"4"}},{"id":1924885,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-04-05T20:03:37.000Z","date":"2023-04-03","kind":"exercise","planned":true,"acquired":true,"shares":16363,"price":9.05,"value":148085.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":134242,"source":{"system":"sec-edgar","filing":"0001439222-23-000058","document":"wf-form4_168072499813992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000058/wf-form4_168072499813992.xml","form_type":"4"}},{"id":1935657,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-03-30T01:30:39.000Z","date":"2023-03-27","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock.  The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone.  The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares.  On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares."}],"balance_after":16363,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-29","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001439222-23-000056","document":"wf-form4_168013982720168.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000056/wf-form4_168013982720168.xml","form_type":"4"}},{"id":1935656,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-30T01:30:39.000Z","date":"2023-03-27","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":22.15,"value":443000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $21.93 to $22.36. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-23-000056","document":"wf-form4_168013982720168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000056/wf-form4_168013982720168.xml","form_type":"4"}},{"id":1935655,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-30T01:30:39.000Z","date":"2023-03-27","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":9.05,"value":181000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":137879,"source":{"system":"sec-edgar","filing":"0001439222-23-000056","document":"wf-form4_168013982720168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000056/wf-form4_168013982720168.xml","form_type":"4"}},{"id":1952090,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-03-15T21:11:56.000Z","date":"2023-03-13","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock.  The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone.  The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares.  On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares."}],"balance_after":36363,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-29","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001439222-23-000055","document":"wf-form4_167891470531005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000055/wf-form4_167891470531005.xml","form_type":"4"}},{"id":1952089,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-15T21:11:56.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":1667,"price":22.72,"value":37874.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $22.67 to $22.81. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-23-000055","document":"wf-form4_167891470531005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000055/wf-form4_167891470531005.xml","form_type":"4"}},{"id":1952088,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-15T21:11:56.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":18333,"price":22.47,"value":411942.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $21.67 to $22.66. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":119546,"source":{"system":"sec-edgar","filing":"0001439222-23-000055","document":"wf-form4_167891470531005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000055/wf-form4_167891470531005.xml","form_type":"4"}},{"id":1952087,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-15T21:11:56.000Z","date":"2023-03-13","kind":"exercise","acquired":true,"shares":20000,"price":9.05,"value":181000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":137879,"source":{"system":"sec-edgar","filing":"0001439222-23-000055","document":"wf-form4_167891470531005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000055/wf-form4_167891470531005.xml","form_type":"4"}},{"id":1983467,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-03-01T21:06:35.000Z","date":"2023-02-27","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock.  The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone.  The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares.  On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares."}],"balance_after":56363,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-29","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001439222-23-000041","document":"wf-form4_167770476285855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000041/wf-form4_167770476285855.xml","form_type":"4"}},{"id":1983466,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-01T21:06:35.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":20000,"price":25.37,"value":507400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $25.11 to $25.74. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-23-000041","document":"wf-form4_167770476285855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000041/wf-form4_167770476285855.xml","form_type":"4"}},{"id":1983465,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-03-01T21:06:35.000Z","date":"2023-02-27","kind":"exercise","acquired":true,"shares":20000,"price":9.05,"value":181000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":137879,"source":{"system":"sec-edgar","filing":"0001439222-23-000041","document":"wf-form4_167770476285855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000041/wf-form4_167770476285855.xml","form_type":"4"}},{"id":2013469,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-02-15T21:03:09.000Z","date":"2023-02-13","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock.  The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone.  The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares.  On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares."}],"balance_after":76363,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-29","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001439222-23-000020","document":"wf-form4_167649497047928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000020/wf-form4_167649497047928.xml","form_type":"4"}},{"id":2013468,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-02-15T21:03:09.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":20000,"price":28.62,"value":572400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.25 to $28.94. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-23-000020","document":"wf-form4_167649497047928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000020/wf-form4_167649497047928.xml","form_type":"4"}},{"id":2013467,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-02-15T21:03:09.000Z","date":"2023-02-13","kind":"exercise","acquired":true,"shares":20000,"price":9.05,"value":181000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":137879,"source":{"system":"sec-edgar","filing":"0001439222-23-000020","document":"wf-form4_167649497047928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000020/wf-form4_167649497047928.xml","form_type":"4"}},{"id":2038434,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-02-01T21:04:33.000Z","date":"2023-01-30","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock.  The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone.  The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares.  On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares."}],"balance_after":96363,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-29","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001439222-23-000010","document":"wf-form4_167528545373635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000010/wf-form4_167528545373635.xml","form_type":"4"}},{"id":2038433,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-02-01T21:04:33.000Z","date":"2023-01-30","kind":"sale","acquired":false,"shares":3300,"price":29.88,"value":98604.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $29.71 to $30.32. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-23-000010","document":"wf-form4_167528545373635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000010/wf-form4_167528545373635.xml","form_type":"4"}},{"id":2038432,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-02-01T21:04:33.000Z","date":"2023-01-30","kind":"sale","acquired":false,"shares":16700,"price":29.22,"value":487974.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.69 to $29.69. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":121179,"source":{"system":"sec-edgar","filing":"0001439222-23-000010","document":"wf-form4_167528545373635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000010/wf-form4_167528545373635.xml","form_type":"4"}},{"id":2038431,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-02-01T21:04:33.000Z","date":"2023-01-30","kind":"exercise","acquired":true,"shares":20000,"price":9.05,"value":181000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":137879,"source":{"system":"sec-edgar","filing":"0001439222-23-000010","document":"wf-form4_167528545373635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000010/wf-form4_167528545373635.xml","form_type":"4"}},{"id":2050753,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-01-19T21:03:43.000Z","date":"2023-01-17","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was originally granted on April 30, 2013 for the purchase of 136,363 shares of common stock.  The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone.  The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 68,181 shares.  On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 68,182 shares."}],"balance_after":116363,"derivative":{"exercise_price":9.05,"expiration_date":"2023-04-29","underlying":"Common stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001439222-23-000008","document":"wf-form4_167416220784481.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000008/wf-form4_167416220784481.xml","form_type":"4"}},{"id":2050752,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-01-19T21:03:43.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":1034,"price":29.49,"value":30492.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $29.42 to $29.65. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-23-000008","document":"wf-form4_167416220784481.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000008/wf-form4_167416220784481.xml","form_type":"4"}},{"id":2050751,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-01-19T21:03:43.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":18966,"price":28.82,"value":546600.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.42 to $29.39. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":118913,"source":{"system":"sec-edgar","filing":"0001439222-23-000008","document":"wf-form4_167416220784481.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000008/wf-form4_167416220784481.xml","form_type":"4"}},{"id":2050750,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-01-19T21:03:43.000Z","date":"2023-01-17","kind":"exercise","acquired":true,"shares":20000,"price":9.05,"value":181000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":137879,"source":{"system":"sec-edgar","filing":"0001439222-23-000008","document":"wf-form4_167416220784481.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000008/wf-form4_167416220784481.xml","form_type":"4"}},{"id":2222987,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2022-06-23T20:12:27.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":29307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023."}],"balance_after":29307,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":29307},"source":{"system":"sec-edgar","filing":"0001439222-22-000066","document":"wf-form4_165601510092788.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000066/wf-form4_165601510092788.xml","form_type":"4"}},{"id":2222986,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-06-23T20:12:27.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":4975,"derivative":{"underlying":"Common stock","underlying_shares":4975},"source":{"system":"sec-edgar","filing":"0001439222-22-000066","document":"wf-form4_165601510092788.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000066/wf-form4_165601510092788.xml","form_type":"4"}},{"id":2242452,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-07T00:09:58.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17959,"derivative":{"exercise_price":24.27,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":17959},"source":{"system":"sec-edgar","filing":"0001714899-22-000098","document":"wf-form4_165456058126311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000098/wf-form4_165456058126311.xml","form_type":"4"}},{"id":2242451,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T00:09:58.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":5986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":11313,"source":{"system":"sec-edgar","filing":"0001714899-22-000098","document":"wf-form4_165456058126311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000098/wf-form4_165456058126311.xml","form_type":"4"}},{"id":2258111,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-05-24T20:11:49.000Z","date":"2022-05-20","kind":"exercise","acquired":false,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"There restricted stock units were granted on May 20, 2021. The shares underlying these restricted stock units vest as to 100% of the underlying shares on May 20, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"There restricted stock units were granted on May 20, 2021. The shares underlying these restricted stock units vest as to 100% of the underlying shares on May 20, 2022."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-22-000051","document":"wf-form4_165342307618924.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000051/wf-form4_165342307618924.xml","form_type":"4"}},{"id":2258110,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2022-05-24T20:11:49.000Z","date":"2022-05-20","kind":"exercise","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":117879,"source":{"system":"sec-edgar","filing":"0001439222-22-000051","document":"wf-form4_165342307618924.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000051/wf-form4_165342307618924.xml","form_type":"4"}},{"id":2378312,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2022-02-23T21:09:46.000Z","date":"2022-02-22","kind":"exercise","acquired":false,"shares":2775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2775},"source":{"system":"sec-edgar","filing":"0001439222-22-000015","document":"wf-form4_164565054852931.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000015/wf-form4_164565054852931.xml","form_type":"4"}},{"id":2378311,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2022-02-23T21:09:46.000Z","date":"2022-02-22","kind":"tax_withholding","acquired":false,"shares":758,"price":29.08,"value":22042.64,"ownership":{"direct":true},"balance_after":116294,"source":{"system":"sec-edgar","filing":"0001439222-22-000015","document":"wf-form4_164565054852931.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000015/wf-form4_164565054852931.xml","form_type":"4"}},{"id":2378310,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2022-02-23T21:09:46.000Z","date":"2022-02-22","kind":"exercise","acquired":true,"shares":2775,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":117052,"source":{"system":"sec-edgar","filing":"0001439222-22-000015","document":"wf-form4_164565054852931.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000015/wf-form4_164565054852931.xml","form_type":"4"}},{"id":2681043,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-04T22:37:06.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":6222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":6222,"derivative":{"exercise_price":63.76,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":6222},"source":{"system":"sec-edgar","filing":"0001209191-21-038390","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038390/doc4.xml","form_type":"4"}},{"id":2681042,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T22:37:06.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":5327,"source":{"system":"sec-edgar","filing":"0001209191-21-038390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038390/doc4.xml","form_type":"4"}},{"id":2683440,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-04T00:57:14.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":3253,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3253},"source":{"system":"sec-edgar","filing":"0001209191-21-038047","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038047/doc4.xml","form_type":"4"}},{"id":2683439,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T00:57:14.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":3253,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3253,"source":{"system":"sec-edgar","filing":"0001209191-21-038047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919121038047/doc4.xml","form_type":"4"}},{"id":2686286,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2021-06-02T20:07:14.000Z","date":"2021-05-28","kind":"exercise","acquired":false,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1686},"source":{"system":"sec-edgar","filing":"0001439222-21-000050","document":"wf-form4_162266441654458.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000050/wf-form4_162266441654458.xml","form_type":"4"}},{"id":2686285,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-06-02T20:07:14.000Z","date":"2021-05-28","kind":"exercise","acquired":true,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":114277,"source":{"system":"sec-edgar","filing":"0001439222-21-000050","document":"wf-form4_162266441654458.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000050/wf-form4_162266441654458.xml","form_type":"4"}},{"id":2698757,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2021-05-24T20:45:25.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022."}],"balance_after":8888,"derivative":{"exercise_price":56.76,"expiration_date":"2031-05-20","underlying":"Common stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001439222-21-000046","document":"wf-form4_162188910802212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000046/wf-form4_162188910802212.xml","form_type":"4"}},{"id":2698756,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2021-05-24T20:45:25.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"}],"balance_after":1585,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-21-000046","document":"wf-form4_162188910802212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000046/wf-form4_162188910802212.xml","form_type":"4"}},{"id":2835712,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2021-02-24T21:12:51.000Z","date":"2021-02-22","kind":"exercise","acquired":false,"shares":2774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":2775,"derivative":{"underlying":"Common stock","underlying_shares":2774},"source":{"system":"sec-edgar","filing":"0001439222-21-000022","document":"wf-form4_161420115567750.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000022/wf-form4_161420115567750.xml","form_type":"4"}},{"id":2835711,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-02-24T21:12:51.000Z","date":"2021-02-22","kind":"tax_withholding","acquired":false,"shares":821,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":112591,"source":{"system":"sec-edgar","filing":"0001439222-21-000022","document":"wf-form4_161420115567750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000022/wf-form4_161420115567750.xml","form_type":"4"}},{"id":2835710,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-02-24T21:12:51.000Z","date":"2021-02-22","kind":"exercise","acquired":true,"shares":2774,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":113412,"source":{"system":"sec-edgar","filing":"0001439222-21-000022","document":"wf-form4_161420115567750.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000022/wf-form4_161420115567750.xml","form_type":"4"}},{"id":2854253,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2021-02-17T21:12:53.000Z","date":"2021-02-16","kind":"exercise","acquired":false,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8125},"source":{"system":"sec-edgar","filing":"0001439222-21-000009","document":"wf-form4_161359634798927.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000009/wf-form4_161359634798927.xml","form_type":"4"}},{"id":2854252,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-02-17T21:12:53.000Z","date":"2021-02-16","kind":"tax_withholding","acquired":false,"shares":2540,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":110638,"source":{"system":"sec-edgar","filing":"0001439222-21-000009","document":"wf-form4_161359634798927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000009/wf-form4_161359634798927.xml","form_type":"4"}},{"id":2854251,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-02-17T21:12:53.000Z","date":"2021-02-16","kind":"exercise","acquired":true,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":113178,"source":{"system":"sec-edgar","filing":"0001439222-21-000009","document":"wf-form4_161359634798927.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000009/wf-form4_161359634798927.xml","form_type":"4"}},{"id":2933120,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-24T02:52:15.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":5000,"price":90.0054,"value":450027.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number is restated pursuant to an internal review of the Reporting Person's holdings, and reflects the consolidation of shares between trusts associated with the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee."}],"balance_after":26232,"source":{"system":"sec-edgar","filing":"0001209191-20-065134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120065134/doc4.xml","form_type":"4"}},{"id":2933119,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-24T02:52:15.000Z","date":"2020-12-21","kind":"sale","acquired":false,"shares":25000,"price":90.0622,"value":2251555.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average price of the shares sold ranging from $90.00 to $90.38 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-065134","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120065134/doc4.xml","form_type":"4"}},{"id":2981477,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-13T22:13:39.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":30000,"price":70.053,"value":2101590.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.305 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-20-058334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120058334/doc4.xml","form_type":"4"}},{"id":2983940,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-12T21:21:00.000Z","date":"2020-11-10","kind":"sale","acquired":false,"shares":10000,"price":60.031,"value":600310.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001209191-20-057936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120057936/doc4.xml","form_type":"4"}},{"id":2989831,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":40558,"kind":"person","name":"Schenkein David P","position":1,"cik":"0001578200","reported_name":"Schenkein David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-06T22:53:19.000Z","date":"2020-11-04","kind":"sale","acquired":false,"shares":10000,"price":50.183,"value":501830.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.00 to $50.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001209191-20-057336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000120919120057336/doc4.xml","form_type":"4"}}],"next_cursor":"2020-11-06T22:53:19.000000Z,2989831"}